Overview

Safety, Tolerability and PK of SHR1314 in axSpA

Status:
Completed
Trial end date:
2020-01-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety, Tolerability and Pharmacokinetics (PK) of SHR1314 with axial spondyloarthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.